Over 9,000 delegates registered for in-person or online attendance at this year’s European Academy of Neurology Congress in Helsinki, Finland (29 June-2 July 2024), with headache presentations including extensive real world data on use of anti-CGRP therapies, together with latest insights into their effects on the migraine brain
Pausing and reintroducing CGRP mAbs after 12 months of continuous use, as required by some reimbursement agencies, reduces treatment effectiveness, according to results of the fourth interim analysis of the Phase 4 PEARL trial of 220 adults with episodic or chronic migraine using fremanezumab. In the study, 196 patients stopped treatment after a mean 11.2 …
Read more »CGRP mAbs induce positive modulation of functional connectivity in the delta and theta bands in patients who respond to treatment. This is the finding from a prospective, real world, open label study in 62 patients with migraine (35 with chronic migraine) who underwent high density (HD)-EEG recordings at baseline and three and six months after …
Read more »Galcanezumab effectively reduces migraine days in patients with medication overuse headache (MOH), irrespective of whether it is combined with prednisone. Results of a prospective observational study of 75 patients with MOH which compared the effectiveness and safety of galcanezumab alone, galcanezumab+prednisone and prednisone alone, showed significant reductions in median monthly headache days (MHD) in all …
Read more »Many CGRP mAb responders who are defined as ‘late’ may in fact be ‘slow’, ie. they achieve a meaningful response at three months and improve with time. This is the conclusion of a prospective analysis of 332 outpatients with migraine, 283 (85.2%) of whom continued CGRP mAb treatment (erenumab, fremanezumab or galcanezumab) for six months. …
Read more »Over half of patients in a real world observational study carried out in Spain had a sustained response to CGRP mAbs (erenumab, fremanezumab and galcanezumab) after two years of treatment. In the study, 148 patients were included, 108 (73%) with chronic migraine. Median baseline monthly headache days (MHD) and monthly migraine days (MMD) were 18 …
Read more »Two thirds of patients using onabotulinumtoxinA to prevent chronic migraine (CM) appear to benefit from adding atogepant to their treatment. In a real world study of 234 patients with CM treated with onabotulinumtoxinA for at least one year, with a stable response for two consecutive 12 week periods between treatments, 211 completed a further 12 …
Read more »Secondary endpoint data reported from a Phase 3 study of a single dose of rimegepant 75 mg ODT in patients with migraine in China and South Korea have confirmed the efficacy of acute treatment for up to 48 hours (NCT04574362).1 In the study of 1,340 patients with 2-8 moderate or severe migraine attacks per month, …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
